These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36600109)

  • 61. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data.
    Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T
    J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Prominent Non-Memory Deficits in Alzheimer's Disease Are Associated with Faster Disease Progression.
    Scheltens NME; Tijms BM; Heymans MW; Rabinovici GD; Cohn-Sheehy BI; Miller BL; Kramer JH; Wolfsgruber S; Wagner M; Kornhuber J; Peters O; Scheltens P; van der Flier WM;
    J Alzheimers Dis; 2018; 65(3):1029-1039. PubMed ID: 30103316
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Modeling Alzheimer's disease progression utilizing clinical trial and ADNI data to predict longitudinal trajectory of CDR-SB.
    Jamalian S; Dolton M; Chanu P; Ramakrishnan V; Franco Y; Wildsmith K; Manser P; Teng E; Jin JY; Quartino A; Hsu JC;
    CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):1029-1042. PubMed ID: 37101394
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Role of Muscle Profile in Alzheimer's Disease: A 3-Year Longitudinal Study.
    Moon Y; Moon WJ; Kim JO; Kwon KJ; Han SH
    Eur Neurol; 2019; 81(5-6):209-215. PubMed ID: 31655799
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Randomized Trial of Verubecestat for Prodromal Alzheimer's Disease.
    Egan MF; Kost J; Voss T; Mukai Y; Aisen PS; Cummings JL; Tariot PN; Vellas B; van Dyck CH; Boada M; Zhang Y; Li W; Furtek C; Mahoney E; Harper Mozley L; Mo Y; Sur C; Michelson D
    N Engl J Med; 2019 Apr; 380(15):1408-1420. PubMed ID: 30970186
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Long-term antipsychotic use and cognitive decline in community-dwelling older adults with mild-moderate Alzheimer disease: Data from NILVAD.
    Dyer AH; Murphy C; Lawlor B; Kennelly SP; For The Nilvad Study Group
    Int J Geriatr Psychiatry; 2021 Nov; 36(11):1708-1721. PubMed ID: 34173272
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease.
    Kandadi Muralidharan K; Tong X; Kowalski KG; Rajagovindan R; Lin L; Budd Haberlain S; Nestorov I
    CPT Pharmacometrics Syst Pharmacol; 2022 Jan; 11(1):7-19. PubMed ID: 34697913
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.
    Ho BL; Kao YH; Chou MC; Yang YH
    J Alzheimers Dis; 2016 Aug; 54(1):351-7. PubMed ID: 27567838
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: A Report of the AAN Guidelines Subcommittee.
    Day GS; Scarmeas N; Dubinsky R; Coerver K; Mostacero A; West B; Wessels SR; Armstrong MJ
    Neurology; 2022 Apr; 98(15):619-631. PubMed ID: 35197360
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial.
    Molloy DW; Standish TI; Zhou Q; Guyatt G;
    Int J Geriatr Psychiatry; 2013 May; 28(5):463-70. PubMed ID: 22718435
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.
    Tai SY; Chen CH; Chien CY; Yang YH
    BMC Neurol; 2017 Feb; 17(1):40. PubMed ID: 28231822
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Vitamin E for Alzheimer's dementia and mild cognitive impairment.
    Farina N; Isaac MG; Clark AR; Rusted J; Tabet N
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD002854. PubMed ID: 23152215
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer's disease.
    Dhadda S; Kanekiyo M; Li D; Swanson CJ; Irizarry M; Berry S; Kramer LD; Berry DA
    Alzheimers Res Ther; 2022 Dec; 14(1):182. PubMed ID: 36482412
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Modeling Alzheimer's Disease Progression Using Disease Onset Time and Disease Trajectory Concepts Applied to CDR-SOB Scores From ADNI.
    Delor I; Charoin JE; Gieschke R; Retout S; Jacqmin P
    CPT Pharmacometrics Syst Pharmacol; 2013 Oct; 2(10):e78. PubMed ID: 24088949
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Seeing with new eyes: finding a path to early intervention trials in Alzheimer's disease.
    Cedarbaum JM; Crans G; Grundman M
    J Nutr Health Aging; 2010 Apr; 14(4):306-9. PubMed ID: 20306002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.